汉霖快讯 | 国际货币基金组织首席经济学家走进复宏汉霖:见证中国经济活力与生物医药创新

梨波儿

近日，国际货币基金组织（IMF）首席经济学家Pierre-Olivier Gourinchas和国际货币基金组织驻华副代表李鑫等一行到访复宏汉霖。Gourinchas先生此次走访调研在沪龙头企业，旨在了解当下中国经济运行情况。



Gourinchas先生一行实地走访了复宏汉霖的制剂和细胞培养实验室，并与复星医药副董事长关晓辉女士、复宏汉霖执行董事、首席执行官兼首席财务官朱俊博士等进行广泛交流和深入探讨，全面了解公司经营状况、技术创新和全球市场拓展情况。









以科技创新为驱动力，以造福全球病患为使命，复宏汉霖携手海外合作伙伴，不断将可负担的高品质生物药推向全球，为全球医疗健康事业发展贡献力量。复宏汉霖自研自产的曲妥珠单抗生物类似药汉曲优®（美国商品名：HERCESSI™，欧洲商品名：Zercepac®）在中国、美国、英国、瑞士、澳大利亚、沙特阿拉伯、巴西等全球40余个国家获批上市，触达亚洲、欧洲、拉丁美洲和大洋洲。公司自研自产的创新生物药抗PD-1单抗H药 汉斯状®（斯鲁利单抗）和利妥昔单抗生物类似药汉利康®也已分别于印度尼西亚和秘鲁获批上市。截至目前，公司五款已上市产品已惠及超过60万患者。

未来，复宏汉霖将继续努力，不断推动技术创新和国际合作，加速为全球患者提供可负担的高品质生物药。”

关于复宏汉霖

复宏汉霖（2696.HK）是一家国际化的创新生物制药公司，致力于为全球患者提供可负担的高品质生物药，产品覆盖肿瘤、自身免疫疾病、眼科疾病等领域，已在中国上市5款产品，在国际获批上市3款产品，23项适应症获批，3个上市申请分别获中国药监局和欧盟EMA受理。自2010年成立以来，复宏汉霖已建成一体化生物制药平台，高效及创新的自主核心能力贯穿研发、生产及商业运营全产业链。公司已建立完善高效的全球创新中心，按照国际药品生产质量管理规范（GMP）标准进行生产和质量管控，不断夯实一体化综合生产平台，其中，公司商业化生产基地已相继获得中国、欧盟和美国GMP认证。

复宏汉霖前瞻性布局了一个多元化、高质量的产品管线，涵盖50多个分子，并全面推进基于自有抗PD-1单抗H药汉斯状®的肿瘤免疫联合疗法。继国内首个生物类似药汉利康®（利妥昔单抗）、自主研发的中美欧三地获批单抗生物类似药汉曲优®（曲妥珠单抗，美国商品名：HERCESSI™，欧洲商品名：Zercepac®）、汉达远®（阿达木单抗）和汉贝泰®（贝伐珠单抗）相继获批上市，创新产品汉斯状®（斯鲁利单抗）已获批用于治疗微卫星高度不稳定（MSI-H）实体瘤、鳞状非小细胞肺癌、广泛期小细胞肺癌和食管鳞状细胞癌，并成为全球首个获批一线治疗小细胞肺癌的抗PD-1单抗。公司亦同步就16个产品在全球范围内开展30多项临床试验，对外授权全面覆盖欧美主流生物药市场和众多新兴市场。

IMF Chief Economist Visits Henlius: Witnessing China's Economic Vitality and Biopharmaceutical Innovation

Recently, Pierre-Olivier Gourinchas, Chief Economist of the International Monetary Fund (IMF), along with IMF Deputy Resident Representative in China Xin Li, visited Henlius. The purpose of Prof. Gourinchas’ visit was to gain a deeper understanding of China's current economic landscape through the lens of leading enterprises in Shanghai.

Prof. Gourinchas and his delegation toured Henlius’ formulation and cell culture laboratories. They engaged in extensive discussions with Ms. Xiaohui Guan, Vice Chairman of Fosun Pharma, and Dr. Jason Zhu, Executive Director, Chief Executive Officer and Chief Financial Officer of Henlius. The discussions focused on the company’s operational status, technological innovations, and global market expansion.

Driven by technology innovation and committed to offering high-quality, affordable and innovative biologic medicines to patients worldwide, Henlius collaborates with its global business partners to continuously bring affordable, high-quality biologics to patients worldwide. Henlius' self-developed and -manufactured trastuzumab biosimilar HANQUYOU (trade name: HERCESSI™ in the U.S. and Zercepac® in Europe) has been approved in over 40 countries, including China, the United States, the United Kingdom, Switzerland, Australia, Saudi Arabia, and Brazil, covering Asia, Europe, Latin America, and Oceania. Additionally, Henlius' self-developed and -manufactured innovative product HANSIZHUANG, an anti-PD-1 monoclonal antibody (mAb), and rituximab biosimilar HANLIKANG, have received approvals in Indonesia and Peru, respectively. To date, the company's five marketed products have benefited over 600,000 patients.

Moving forward, Henlius will continue to strive for technological innovation and global collaboration, accelerating the provision of affordable, high-quality biologics for patients worldwide.”

About Henlius

Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. Up to date, 5 products have been launched in China, 3 have been approved for marketing in overseas markets, 23 indications are approved worldwide, and 3 marketing applications have been accepted for review in China and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centre and Shanghai-based commercial manufacturing facilities certificated by China, the EU and U.S. GMP.

Henlius has pro-actively built a diversified and high-quality product pipeline covering over 50 molecules and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as backbone. Apart from the launched products HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe), a China-developed mAb biosimilar approved in China, Europe and U.S., HANDAYUAN (adalimumab) and HANBEITAI (bevacizumab), the innovative product HANSIZHUANG has been approved by the NMPA for the treatment of MSI-H solid tumours, squamous non-small cell lung cancer (sqNSCLC) and extensive-stage small cell lung cancer (ES-SCLC), and esophageal squamous cell carcinoma (ESCC), making it the world’s first anti-PD-1 mAb for the first-line treatment of SCLC. What’s more, Henlius has conducted over 30 clinical studies for 16 products, expanding its presence in major markets as well as emerging markets.   





喜欢本文内容

点击下方按钮·分享 ·收藏 ·点赞 ·在看

作者：复宏汉霖